You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 5, 2025

Details for Patent: 4,005,063


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,005,063
Title: [Des-gly].sup.10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
Abstract:An unnatural nonapeptide with improved biological activities surpassing those of the natural follicle-stimulating lutenizing hormone-releasing hormone (Gn--RH) is described. The new peptide induces ovulation in warm-blooded animals at an oral dose of 5-100 .mu.g./kg.
Inventor(s): Gendrich; Ronald Lee (Waukegan, IL), Rippel; Riemond Henry (Gurnee, IL), Seely; John Hunter (Lake Bluff, IL)
Assignee: Abbott Laboratories (North Chicago, IL)
Application Number:05/577,815
Patent Claim Types:
see list of patent claims
Compound;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 4,005,063

Introduction

United States Patent 4,005,063 is a significant patent that has been the subject of various legal and regulatory discussions. To understand its implications, it is crucial to delve into its scope, claims, and the broader patent landscape.

Patent Overview

U.S. Patent 4,005,063 was originally set to expire on January 25, 1994, but it received a two-year extension, resulting in a new expiration date of January 25, 1996[1][2].

Scope of the Patent

The scope of a patent is defined by its claims, which outline the specific rights granted to the patent holder. For U.S. Patent 4,005,063, the claims would have been carefully crafted to define the invention and distinguish it from prior art.

  • Claim Language: The claims of a patent are critical in determining its scope. Research suggests that the length and count of independent claims can be metrics for measuring patent scope. Narrower claims tend to have a higher probability of grant and a shorter examination process[3].

Claims Analysis

While the specific claims of U.S. Patent 4,005,063 are not detailed here, it is important to note that claims analysis involves examining the language and breadth of the claims.

  • Independent Claims: Independent claims are those that stand alone and do not depend on other claims. They are often more broad and define the core invention. The length and count of these claims can influence the overall scope of the patent[3].

Patent Landscape

The patent landscape surrounding U.S. Patent 4,005,063 includes other related patents and exclusivities.

  • Related Patents: The patent in question is part of a larger set of patents that may have been filed by the same inventors or companies. For instance, the case involving TAP Pharmaceutical Products mentions several other patents (e.g., U.S. Patent Nos. 4,652,441, 4,677,191, 4,728,721, 4,849,228, and 4,917,893) that were also subject to false marking allegations[1].

Exclusivities and Extensions

Patent exclusivities and extensions play a significant role in the patent landscape.

  • Patent Term Extensions: U.S. Patent 4,005,063 received a two-year extension, which is a common practice to extend the life of a patent. This extension can significantly impact the market exclusivity period for the patented product[1][2].

Impact on Market and Innovation

The marking and false marking of patents can have substantial effects on the market and innovation.

  • False Marking: False marking of expired patents can deter innovation and stifle competition. It can dissuade potential competitors from entering the market and may lead to unnecessary investment in design-around strategies or litigation costs[1].

Regulatory and Legal Context

The regulatory and legal context surrounding U.S. Patent 4,005,063 is crucial.

  • Federal Patent Policy: Federal patent policy aims to promote full and free competition in the use of ideas that are in the public domain. The marking and false marking statutes are designed to give the public notice of patent rights and prevent false claims that could mislead competitors and the public[1].

Case Studies and Examples

Real-world cases provide valuable insights into the implications of patent marking and scope.

  • TAP Pharmaceutical Products Case: The case against TAP Pharmaceutical Products highlights the consequences of false marking. The company faced significant legal and financial repercussions for illegally marketing their products and falsely marking expired patents[1].

Key Takeaways

  • Patent Scope: The scope of a patent is defined by its claims, and metrics such as independent claim length and count can measure this scope.
  • Extensions and Exclusivities: Patent term extensions can significantly impact market exclusivity.
  • False Marking: False marking of patents can deter innovation and stifle competition.
  • Regulatory Context: Federal patent policy aims to promote competition and prevent false marking.

FAQs

Q: What was the original expiration date of U.S. Patent 4,005,063? A: The original expiration date was January 25, 1994, but it was extended to January 25, 1996[1][2].

Q: Why is the scope of a patent important? A: The scope of a patent, defined by its claims, determines the specific rights granted to the patent holder and influences the patent's impact on the market and innovation[3].

Q: What are the consequences of false marking of patents? A: False marking can deter innovation, stifle competition, and lead to legal and financial repercussions[1].

Q: How do patent term extensions affect market exclusivity? A: Patent term extensions can extend the market exclusivity period for the patented product, impacting when generic versions can enter the market[1][2].

Q: What role does federal patent policy play in preventing false marking? A: Federal patent policy aims to prevent false marking by encouraging private parties to enforce the marking statutes and providing public notice of patent rights[1].

Sources

  1. UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT: Case 2:10-cv-00246-TJW Document 1 Filed 07/16/10.
  2. FDA: Untitled - accessdata.fda.gov.
  3. SSRN: Patent Claims and Patent Scope.
  4. USPTO: Drug patent and exclusivity study.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 4,005,063

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

International Family Members for US Patent 4,005,063

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Bulgaria 60340 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 1 of 1 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.